Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Arrow Therapeutics HCV Compound Enters Phase I

28 Nov 2006 - Arrow Therapeutics, a London based antiviral drug discovery and development company, has announced that it has initiated a Phase I study of A-831, a small molecule antiviral inhibitor of Hepatitis C infection. The study shall evaluate the safety, tolerability and pharmacokinetics of single escalating doses of A-831 in healthy volunteers in the UK.
 
A-831 targets the NS5a protein and is, according to the company, the first NS5a inhibitor to enter the clinic. A-831 is the first compound from Arrow's approach to the NS5a target. A further Arrow compound, also targeting the NS5a protein but of a completely different chemical structure, is expected to enter preclinical development shortly.